BiotechCorp is the Malaysian Biotechnology Industry Association (MBIA) and the largest biotech industry association in Malaysia and acts as a one-stop-shop to provide support and advice to biotechnology and life science companies across Malaysia.
It was mentioned in this article.
But before that, here's an update:
Malaysia offers more opportunities for investors, a patent-friendly environment, and is home to some of the world's largest biotechnology companies such as:
- Biosciences International
- Biopharmaceuticals International
- Biomarkers International
BioNexus Status companies are international Malaysian biotech companies that qualify for tax incentives, grants, and guarantees managed by BiotechCorp.
Malaysia has positioned itself as a key player in the global biotechnology and life sciences industry, which is expected to contribute to knowledge and GDP.
Industry players have largely accepted the need to set up research and development centers and public-private partnerships to encourage innovation.
To promote a smooth interface between science and the biotechnology industry, internationally renowned research institutions such as the University of Malaysia, the National Institute of Science and Technology of Malaysia (NITM), the Malaysian Academy of Sciences (MAS), and other universities are working together to provide a platform for more joint ventures and partnerships.
The Malaysian Association of Biotechnology and Life Sciences (BIA) has developed a comprehensive plan to develop tailor-made incentives for research and development in the sector.
To initiate these steps, AIBA SC has facilitated the signature of three Memoranda of Understanding (MoUs) with the Malaysian Government to strengthen cooperation between the biotechnology industry and the private sector in the field of research and development.
"These joint ventures will help develop new processes and techniques, "said an AIBA official.
With 78 participants from over 20 countries in Asia, Europe, Africa, Latin America, Asia-Pacific, and the Middle East, Malaysia is now ready to present new offerings to global partners in the biomedical sector, including OECD and GLP - accredited services.
Several government agencies were also present, with the Ministry of Science, Technology, and Innovation (MSTI), the National Institutes of Health (NIH), and the National Academy of Sciences (NAS) presenting their expertise in biomedical research and development.
The Singapore Bio - Innovations branch of EDB has a long history of commercializing local inventions, making it one of the largest biotechnology and innovation centers in the world.
With a local base now established, the company is now strongly focused on actively promoting the development of new research and development opportunities in the biomedical industry in Malaysia.
The opening ceremony of the Malaysian Pavilion began with the presentation of a document highlighting the achievements of the Malaysian biomedical research, development, and commercialization sector.
This new publication, published last December, provides an insight into the state of the biotech industry in Malaysia. It is jointly published by the Malaysian Biotechnology Industry Association (MBIA) and the Singapore Biotech Research Institute (SBII).
At the second Biotechnology Trends Symposium held in Malaysia, the Managing Director of the Malaysian Biosciences Association of Malaysia (BIOM), Dr. Mohd Zainal Abidin, said that there is still a need for more research, development, and commercialization opportunities in the biomedical industry.
A recent conference here focused on the evolving biotechnology landscape in Malaysia and the need to raise awareness of the industry's potential and growth potential.
Recently, the Malaysian Biotechnology Industry Association (MBIA) and SBII, as well as the science-based industry, have been able to draw on valuable new resources.
The event included presentations from 17 biotechnology companies based in Hong Kong, Singapore, Malaysia, Indonesia, China, India, Japan, South Korea, Australia, and New Zealand.
The projects presented were part of the R & D pipeline aimed at the development and commercialization of biotechnological products and services in the biotechnology industry.
India is the second of 4,000 pharmaceutical companies, according to the India Brand Equity Foundation, which also lists 800 biotechnologies.
More than half of biotech startups in India are women, one of which is headed by Kiran Mazumdar Shaw in Bangalore - based at Biocon. The lead includes more than 1,000 biotech start-ups created between 2012 and 2016, with a further 500 founded in 2017.
According to the World Economic Forum's 2017 Global Competitiveness Report, the Association of Southeast Asian Nations (ASEAN) is on track to become Asia's next economic powerhouse.
South Korea has promoted multinationals and small businesses, many of which deserve the label Innovative Pharmaceutical Company, showing officials that they have a high level of research and development capacity, are globally competitive, and have a strong track record of innovation.
ASEAN harmonization is an attempt to create a common framework for the regulation of pharmaceutical, biotechnological, and biopharmaceutical products and services in the region.
The ten ASEAN member countries have adopted the Harmonised Medicinal Products Registration Act (HPRA), which provides legal clarity for companies to register their products in A SEAN.
No comments:
Post a Comment